EndoChoice® Announces Carnegie Hill Endoscopy as First Center of Excellence for Fuse® Endoscopy System

ATLANTA, May 19, 2014 /PRNewswire/ -- EndoChoice^® today announced Carnegie Hill Endoscopy of New York City has become the first center in the world to receive 'Center of Excellence' designation for the revolutionary Fuse^® Full Spectrum Endoscopy™ system.

Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The Fuse system uses three small cameras at the tip of a flexible GI endoscope, as compared with one at the tip of a standard, forward-viewing endoscope.  With a wider 330 degree view, physicians see nearly twice the surface area and anatomy of the colon, including behind and into folds. A recent clinical study found that up to 41% of potentially pre-cancerous polyps hide and go undetected with the limited 170 degree view of standard, forward-viewing endoscopes.

Comprised of 22 physicians, Carnegie Hill Endoscopy, an affiliate of the Mount Sinai Health System, is one of the most innovative and prestigious endoscopy centers in the United States. The Carnegie Hill Endoscopy center has always been committed to state-of-the-art services, and re-fitted all five of their procedure rooms to Fuse endoscopy systems exclusively. 

"This invention could not come at a better time.  The length of time between recommended colonoscopies has been increasing and now a patient considered at low risk for colon cancer is told to wait ten years between exams.  If the patient is to wait that long, we should do our best to assure that no polyps are present," said Blair Lewis, M.D., Medical Director of Carnegie Hill Endoscopy and Clinical Professor of Medicine with the Icahn School of Medicine at Mount Sinai.  "Finding and removing more pre-cancerous polyps directly reduces the risk of developing cancer between colonoscopies."

"After years of research and development, we are pleased to make this revolutionary technology available to patients," said Mark Gilreath, Founder and CEO at EndoChoice. "It's encouraging to see leading physicians across the United States embrace the technology.  Physicians will miss fewer polyps, and lives will be saved.  It's clear that patients will ultimately choose GI physicians and centers that offer Full Spectrum Endoscopy."

About EndoChoice
Based in Atlanta GA, EndoChoice^® is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases.  EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide.  The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse^®). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine.  To learn more, visit www.endochoice.com

EndoChoice^® and Fuse^® are registered trademarks of EndoChoice, Inc.

For more information, press only:

Doug Ladd, Chief Marketing Officer
513-608-6873 or [email protected]

For more information on Fuse^®

www.endochoice.com/fuseor www.fusecolonoscopy.org

SOURCE EndoChoice